{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-116774","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.874199+00:00","generated_at":"2026-05-30T01:55:47.001470+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Theravance Biopharma Q3 2024: YUPELRI sales record $62.2M (+7%); net loss widens; board forms strategic review","bullets":["Total revenue $16.9M (Viatris collab); implied YUPELRI net sales $62.2M all-time high (7% YoY, 14% QoQ).","Net loss $12.7M vs $9.0M YoY; non-GAAP net loss from operations $2.9M vs $0.7M.","TRELEGY milestone: Q4 sales ~$260M needed for $25M payment, ~$610M for $50M; YTD sales $2.6B.","Board forms Strategic Review Committee to assess alternatives to unlock shareholder value.","CYPRESS (ampreloxetine) open-label enrollment on track for mid-2025 completion; data ~6 months later."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-116774","json":"https://secwatch.observer/filing/0001104659-24-116774.json","markdown":"https://secwatch.observer/filing/0001104659-24-116774.md","text":"https://secwatch.observer/filing/0001104659-24-116774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924116774/0001104659-24-116774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924116774/tm2428109d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:55:47.001470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}